| Document |
Document Title |
|
WO/2023/033890A1 |
Additives for energy storage devices comprising nitrogen-containing compounds are disclosed. The energy storage device comprises a first electrode and a second electrode, where at least one of the first electrode and the second electrode...
|
|
WO/2022/065730A1 |
Provided is a cyano group-substituted aryl or heteroaryl derivative which effectively absorbs high-energy light in the UV region from an external light source to minimize damage to organic materials inside an organic electroluminescent d...
|
|
WO/2021/246231A1 |
This ammonium zinc molybdate hydrate for an electronic material has a structure represented by the following chemical formula. H3O)(NH4)Zn2Mo2O9
|
|
WO/2021/102568A1 |
This disclosure relates generally to cannabinoid derivatives having the structural formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives. In some embodiments, R1 is - CH2CH=C(CH3)2, R2...
|
|
WO/2020/254558A1 |
The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the ClC...
|
|
WO/2020/059476A1 |
The present invention provides a cyanic acid ester compound represented by formula (1). In formula (1), each of R1, R2, R3 and R4 independently represents a monovalent substituent that is a hydrogen atom, a linear or branched alkyl group...
|
|
WO/2019/198626A1 |
A cyanic acid ester compound represented by formula (1). (In formula (1), R's each independently represent a hydrogen atom, a linear or branched C1-6 alkyl group, or a halogen atom, and n is an integer of 1-4.)
|
|
WO/2019/198550A1 |
Provided are: a cyanic acid ester compound which can exhibit excellent heat conductivity; a method for producing the cyanic acid ester compound; a resin composition; a cured article; a single-layer resin sheet; a laminated resin sheet; a...
|
|
WO/2019/013299A1 |
The present invention provides a thermally conductive material that has excellent thermal conductivity. The present invention also provides: a device that is provided with a thermally conductive layer that includes the thermally conducti...
|
|
WO/2016/158066A1 |
The present invention provides a novel cyanic acid ester compound capable of giving a cured object which has excellent solubility in solvents and a low coefficient of thermal expansion and is excellent in terms of flame retardancy and he...
|
|
WO/2016/058056A1 |
The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal centre, particularly for the imaging of tumours.
|
|
WO/2016/021511A1 |
This underlayer film-forming composition for lithography contains a compound represented by specific formula (1) and 20 to 99 mass% of a solvent component (S), wherein the compound represented by formula (1) comprises 27 to 100 mass% of ...
|
|
WO/2015/168465A1 |
This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.
|
|
WO/2015/060418A1 |
Provided is a novel cyanic acid ester compound which has excellent solubility in solvents and enables the production of a cured article having a low thermal expansion coefficient and excellent flame retardancy and heat resistance. The pr...
|
|
WO/2014/143561A1 |
Compounds of formula (I): where R1, R2, R3, R4a, R4b, R5, R6 and R7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may b...
|
|
WO/2014/065422A9 |
The present invention addresses the problem of providing: an efficient production method for a cyanogen halide with which secondary reactions are inhibited in the production of cyanate ester compounds; and a production method with which ...
|
|
WO/2014/040052A2 |
The present application relates to: (a) compounds of Formula (I): and salts thereof, wherein Y and Z are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, sal...
|
|
WO/2013/126643A1 |
Disclosed herein are polycyanates of the formula: where R, m, Q, p and Z are as defined herein. Also disclosed are methods of curing said polycyanates and methods of using said polycyanates to provide high Tg thermoset products.
|
|
WO/2012/121146A1 |
Electrode active material has an organic compound as a principal constituent thereof that contains a pyracene structure represented by the general formula as a constitutional unit thereof. This pyracene structure contains a plurality of ...
|
|
WO/2012/106588A2 |
The present invention encompasses the finding that improvements can be achieved in manufacture of isocyanates through the use of a substitute for or a precursor of phosgene. Methods and compositions utilized in accordance with the presen...
|
|
WO/2012/057144A1 |
Provided is a novel difunctional cyanate ester of a di-cyanatophenyl type, which can obtain a cured product that is in liquid form at room temperature and has excellent low thermal expansion. A cyanate ester compound represented by formu...
|
|
WO/2012/029672A1 |
The present invention relates to amine derivatives each represented by chemical formula (I) (wherein Ar represents a phenyl group or the like; R1 represents a hydrogen atom or the like; R2 represents a C1-6 alkylcarbonyl group or the lik...
|
|
WO/2011/136844A1 |
Embodiments of the present disclosure include polycyclopentadiene compounds represented by Formula (I) : in which each X is either a hydrogen or a cyano group ( N≡C-), n has an average value from zero to 20; each m independently has a ...
|
|
WO/2011/110653A1 |
Solution of conductive molecular materials and electromagnetic absorbents produced from these solutions. The invention relates to a stable solution of molecular material, characterized in that it comprises: - a first type of organic or o...
|
|
WO/2011/085280A1 |
Disclosed herein are compositions comprising a reactive monomer, and, in particular, coating and/or reactive coating compositions. More particularly, compositions containing monomers comprising a lactam moiety, a urethane or urea functio...
|
|
WO/2011/022457A1 |
Compounds comprising a lactam moiety, and a urethane or urea functional group are presented. By a preferred synthesis route, they are prepared using at least one polymerizable compound comprising an isocyanate moiety and reacting it with...
|
|
WO/2010/123838A2 |
The present invention relates to inhibitors of 11- β-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, centr...
|
|
WO/2010/101294A1 |
There is provided an antistatic agent for a polyurethane resin which exhibits sufficient antistatic properties with a smaller addition amount and in which an effective component has no halogen atom. As the effective component of an antis...
|
|
WO/2010/064655A1 |
An indenofluorenedione derivative having a structure represented by formula (I) (wherein Ar1 represents a fused ring having 6-24 nuclear carbon atoms, or the like; ar1 and ar2 represent formula (i) or/and formula (ii); and x1 and x2 each...
|
|
WO/2010/010174A1 |
The present invention relates to compounds defined by formula (I) wherein the group R is defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase...
|
|
WO/2009/114465A1 |
Aromatic dicyanate compounds which comprise aliphatic moieties having at least about six carbon atoms and resins and thermoset products based on these compounds.
|
|
WO/2009/011327A1 |
Disclosed is an organic electroluminescent device material containing an indenofluorenedione derivative represented by the following formula (I). (In the formula, X1 and X2 may be the same or different and each represents a specific diva...
|
|
WO/2008/074755A2 |
This invention relates to novel cinnamic amide derivatives that are found to be potent modulators of ion channels and, as such, they are valuable candidates for the treatment of diseases or disorders as diverse as those which are respons...
|
|
WO/2007/116750A1 |
Disclosed is a material for organic electroluminescent devices which contains a quinone derivative represented by one of the formulae (1)-(3) below. [In the formulae, R1-R16 respectively represent a hydrogen, a halogen, a cyano group, an...
|
|
WO/2006/124710A1 |
The present invention is directed to D-homoandrosta-17-yl-carbamate derivatives as selective glucocorticoid receptor ligands useful for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions...
|
|
WO/2006/088556A1 |
Charge transport materials are provided, and methods for making the same.
|
|
WO/2006/038606A1 |
Disclosed are a compound represented by the formula (I) below, a pharmaceutically acceptable salt thereof, a solvate of those, and a pharmaceutical composition containing such a compound. (In the formula, X1 represents N or CR2; X2 repre...
|
|
WO/2006/017406A1 |
cyanoamidines compounds of formula (I) and (II) and their derivatives wherein R1 - R12 are as defined in the specification act as antagonists of the P2X7 receptor. These compounds are particularly useful in the treatment of pain, inflamm...
|
|
WO/2005/068412A1 |
The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders c...
|
|
WO/2005/054174A2 |
The invention relates to compounds for modulating the glycolysis enzyme complex and the transaminase complex, pharmaceutical compositions containing said compounds, and to the uses of said compounds for the production of pharmaceutical c...
|
|
WO/2005/007104A2 |
The invention provides the following formula (I) and uses thereof: wherein each Ak is independently selected from the group consisting of alkyl; Cy is selected from the group consisting of cycloalkyl, substituted cycloalkyl, heterocycle,...
|
|
WO/2004/101501A1 |
The invention relates to a novel method for producing dimethyl cyanimidocarbonate (DCC, 3,3-dimethoxy-2-azaprop-2-ene nitrile) from sodium cyanide, methanol, chlorine gas and cyanamide.
|
|
WO/2004/098512A2 |
The present application describes modulators of MCP 1 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
|
|
WO/2004/089890A2 |
Disclosed is a new process and intermediates for preparing benzazepines of Formula wherein R1 and R2 are as defined herein.
|
|
WO/2004/052847A2 |
The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula...
|
|
WO2004005244B1 |
The invention relates to a method for producing O-alkyl-N-cyanoformimidates, during which the reaction of cyanamide with orthoformic acid alkyl esters ensues with a molar ratio of 1: 0.8 to 10.0 without the addition of a catalyst, at pre...
|
|
WO/2003/104184A1 |
The synthesis of 1-(acyloxy)-alkyl carbamates of GABA analogs from 1-haloalkyl carbamates of GABA analogs are described. Also described are new 1-haloalkyl carbamates of GABA analogs.
|
|
WO/2003/095418A1 |
The invention relates to novel N'-cyano-N-methyl-imidamide derivatives of general formula (I) wherein n represents 2, 3, 4 or 5, R represents optionally halogen-substituted C1-C4-alkyl, and X represents Halogen, wherein the substituents ...
|
|
WO/2003/086325A2 |
Compounds according to the following formula (I): wherein the variables Q and Rl to R6 are as described herein, which reversibly inhibit the cysteine proteases, such as cathepsins K, S, F, L and B; pharmaceutical compositions containing ...
|
|
WO/2003/074473A2 |
In one embodiment, this invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). The SARM compounds have unexpected a...
|
